William D Clark
CIK 1355415 · President and CEO · last filed 2026-06-11
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$870.9K
Companies
5
Total Filings
49
Lifetime Open-Market Net
-$2.75M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALDX | Director | — | $1.58 | — | $0 | 2 | 2026-06-11 |
| IBIO | Director | 1,838 | $1.39 | $2.6K | $5.0K | 5 | 2025-11-24 |
| GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | President and CEO | 304,377 | $0.00 | $183 | $39.1K | 22 | 2022-06-03 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | — | $0.08 | — | $0 | 3 | 2018-06-07 |
| VNDA | Sr. VP, Chief Business Officer | 168,279 | $5.16 | $868.3K | -$2.80M | 17 | 2010-02-23 |
Recent Filings · Page 2 of 5
49 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-08-25 | IBIO | Grant (A) | — | $0 | EDGAR |
| 2021-03-17 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | +150,000 | $0 | EDGAR |
| 2021-02-18 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Exer (M) | +36,498 | $81.8K | EDGAR |
| 2020-11-10 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Buy (P) | +4,760 | $9.8K | EDGAR |
| 2020-06-02 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | +27,344 | $0 | EDGAR |
| 2020-04-06 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | +50,783 | $0 | EDGAR |
| 2019-03-18 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Exer (M) | +15,000 | $8.1K | EDGAR |
| 2019-02-11 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | GENOCEA BIOSCIENCES, INC. (GNCA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-07 | X4 Pharmaceuticals, Inc (ASNS) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.